Craig-Hallum starts Lineage Cell Therapeutics at Buy on OpRegen opportunity

As previously reported, Craig-Hallum initiated coverage of Lineage Cell Therapeutics (LCTX) with a Buy rating and $4 price target. The firm views lead program OpRegen as “an innovative therapy for dry AMD” that also validates Lineage’s stem cell-based platform and sees opportunity for share appreciation as data in additional patients from the ongoing Phase IIa trial by collaborator Genentech (RHHBY) reaffirms OpRegen’s efficacy. The firm believe OpRegen’s ability to preserve or restore vision “represents a paradigm shift in AMD therapy” and positions Lineage as “the leader in the emerging field of stem-cell based therapies for regenerative medicine,” the analyst tells investors.